Journal update monthly top five
The ARISE FLUIDS trial suggests a potential paradigm shift in early septic shock management, questioning the indefinite continuation of aggressive fluids. If the data holds, this supports a more timely transition to vasopressors rather than relying solely on fluid boluses once initial resuscitation efforts are underway. Remember to critically appraise the timing of vasopressor initiation versus the current institutional threshold for fluid cessation.
The latest roundup from the Johns Hopkins Emergency Department team highlights five key papers across various emergency topics, using a multimodal search approach to curate the most relevant literature for emergency physicians. The authors categorize these findings as 'Worth a peek,' 'Head turner,' or 'Game changer,' suggesting a hierarchy of clinical impact. Of particular note is the ARISE FLUIDS trial, a multicenter, open-label randomized controlled trial addressing the management of early septic shock. This study directly compares the continuation of aggressive fluid resuscitation versus the earlier initiation of vasopressors once resuscitation has begun. Given its focus on shifting the balance between fluid and pressor support in the critically ill septic patient, the authors classify this as a potential 'Game Changer' for current sepsis protocols.